Sundet, Birgitte Kordt
Kreyberg, Ina
Staff, Anne Cathrine
Carlsen, Karin Cecilie Lødrup
Bains, Karen Eline Stensby
Berg, Jens Petter
Granum, Berit
Haugen, Guttorm
Hedlin, Gunilla
Jonassen, Christine Monceyron
Nordhagen, Live Solveig
Nordlund, Björn
Rehbinder, Eva Maria
Rudi, Knut
Rueegg, Corina Silvia
Sjøborg, Katrine Dønvold
Skjerven, Håvard Ove
Söderhäll, Cilla
Vettukattil, Riyas
Sugulle, Meryam http://orcid.org/0000-0003-4160-3978
Article History
Received: 6 October 2021
Accepted: 14 June 2022
First Online: 15 July 2022
Declarations
:
: The Regional Committee for Medical and Health Research Ethics in South-Eastern Norway (2014/518; December 8th, 2014) and Ethics committee in Sweden (2014/2242–31/4) approved the study. PreventADALL is registered in ClinicalTrials.gov, with reference number NCT02449850. Written, informed consent was obtained during the enrolment visit at the routine second trimester ultrasound screening.
: Not applicable.
: Meryam Sugulle and Anne Cathrine Staff have received in-kind reagents for the sFlt-1 and PlGF biomarker analyses from Roche Diagnostics (Rotkreuz, Switzerland), but Roche Diagnostics had no impact on planning, performance or other aspects of the study.The authors declare that they have no competing interests.